Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201
Status:
WITHDRAWN
Trial end date:
2029-02-01
Target enrollment:
Participant gender:
Summary
This clinical trial will enroll subjects with HER2+ solid tumors and is conducted in two phases, which are phase 1a and phase 1b. The primary objective of phase 1 is to determine the safety and tolerability of AB-201 in subjects with advanced HER2+ solid tumors.